North America Cancer Monoclonal Antibodies Market by application (Liver, Breast, Blood, Brain, Hodgkin’s and Non-Hodgkin’s lymphoma, Colorectal, leukaemia and others) by type (murine antibodies, chimeric and humanised antibodies and fully humanized antibodies) by Conjugated Cancer therapies and by region - Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)

North America Cancer Monoclonal Antibodies Market by application (Liver, Breast, Blood, Brain, Hodgkin’s and Non-Hodgkin’s lymphoma, Colorectal, leukaemia and others) by type (murine antibodies, chimeric and humanised antibodies and fully humanized antibodies) by Conjugated Cancer therapies and by region - Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)

ID: 187 | Pages: 132 | December 2016 | Region: North America


North America Monoclonal Antibodies Market is estimated to be a USD 10.26 billion market in 2015 and is expected to reach USD 17 billion market by the end of 2020 with a significant growth rate of 10.5%. Cancer is the leading cause of death currently across the globe. It starts with a single cell genetically transforming normal cell into tumour and is spread gradually to the other cells. The dramatic increases in the number of cancer cases has prompted many pharmaceutical companies to invest in monoclonal antibodies. The practise for curing cancer currently include usage of drugs and chemotherapy which have adverse side effects. This persuade the usage of Monoclonal antibodies.

Recent years have seen the emergence of monoclonal antibodies market, offering less toxic and highly efficient therapeutics alternatives. The antibody agents are used to cure a wide array of diseases, especially cancer, autoimmune and inflammatory diseases. They are mono-specific antibodies having identical immune cells that are clone to the single parent cells and are directed to a specific target cell. This customizable feature of the antibodies due to its specific nature can play a critical role in eliminating the cancer cell while sparing the healthy cells. Monoclonal antibodies are more effective in treating cancer than their counter parts like drugs or chemotherapy owing to their adverse side effects.

The drastic increase in the people affected by cancer prompted many pharmaceutical firms to invest in monoclonal antibodies. Rise in investment in R&D of genomic studies, technological innovations in target gene selection and genetic sequencing, monoclonal antibodies ability to target only specific cells, having no side effects compared to its counter parts are the primary drivers for the market. With the increased occurrence of cancer, the market is expected to grow significantly in the next 5 years having a presence of highly strong products in the pipeline. There are also few restraints for its market entry like high cost, stringent guidelines, long durations required for R&D, clinical trials.

The North America Monoclonal Antibodies are categorised on the basis of application as Breast, Brain, blood, Liver, Hodgkins and Non-Hodgkins lymphoma, leukaemia, colorectal and others. The market is again segmented based on type as chimeric and humanised antibodies, murine antibodies and fully humanized antibodies. The market is again divided into various categories by conjugated cancer therapies as Radoimmunotherapy, ADEPT, Immunoliposome, immunocytokines and others. Based on the geographical region of North America it is segmented into US and Canada.

The major companies in this industry are Amgen, Genmab, Briston Myers squibb, glaxosmithkline, Eli Lilly, Roche, Immunogen, Seattle Genetics, Novartis and Spectrum Pharmaceuticals.

 

  1. Introduction

                1.1 Market Definition                                                                                    

                1.2 Study Deliverables                                                                                  

                1.3 Base Currency, Base Year and Forecast Periods                                                                                          

                1.4 General Study Assumptions                                                                                

  1. Research Methodology

                2.1 Introduction                                                                                               

                2.2 Research Phases                                                                                      

                                2.2.1 Secondary Research                                                                           

                                2.2.2 Primary Research                                                                 

                                2.2.3 Econometric Modelling                                                                      

                                2.2.4 Expert Validation                                                                  

                2.3 Analysis Design                                                                                         

                2.4 Study Timeline                                                                                          

  1. Overview

                3.1 Executive Summary                                                                                

                3.2 Key Inferences                                                                                         

                3.3 New Developments                                                                                               

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers                                                                                          

                4.2 Market Restraints                                                                                    

                4.3 Key Challenges                                                                                         

                4.4 Current Opportunities in the Market                                                                                              

  1. Market Segmentation

                5.1 By Application                                                                                           

                                5.1.1 Liver                                                                           

                                5.1.2 Breast                                                                       

                                5.1.3 Brain                                                                          

                                5.1.4 Blood                                                                         

                                5.1.5 Hodgkins and Non-Hodgkins lymphoma                                                                    

                                5.1.6 Colorectal                                                                

                                5.1.7 Leukaemia                                                                              

                                5.1.8 Others                                                                      

                5.2 By Type                                                                                        

                                5.2.1 Murine Antibodies                                                                              

                                5.2.2 Chimeric and Humanised Antibodies                                                                           

                                5.2.3 Fully Humanized Antibodies                                                                            

                5.3 Conjugate Cancer Therapies                                                                                               

                                5.3.1 Immunoliposome                                                                

                                5.3.2 Radioimmunotherapy                                                                        

                                5.3.3 ADEPT                                                                       

                                5.3.4 Immunocytokines                                                                

                                5.3.5 Others                                                                      

  1. Geographical Analysis

                6.1 Introduction                                                                                               

                6.2 United States                                                                                            

                6.3 Canada                                                                                         

  1. Strategic Analysis

                7.1 PESTLE analysis                                                                                         

                                7.1.1 Political                                                                     

                                7.1.2 Economic                                                                 

                                7.1.3 Social                                                                         

                                7.1.4 Technological                                                                         

                                7.1.5 Legal                                                                          

                                7.1.6 Environmental                                                                       

                7.2 Porter’s Five analysis                                                                                              

                                7.2.1 Bargaining Power of Suppliers                                                                        

                                7.2.2 Bargaining Power of Consumers                                                                    

                                7.2.3 Threat of New Entrants                                                                     

                                7.2.4 Threat of Substitute Products and Services                                                                              

                                7.2.5 Competitive Rivalry within the Industry                                                                     

  1. Market Leaders' Analysis

                8.1 Roche                                                                           

                                8.1.1 Overview                                                                 

                                8.1.2 Product Analysis                                                                   

                                8.1.3 Strategic Evaluation and Operations                                                                            

                                8.1.4 Financial analysis                                                                  

                                8.1.5 Legal issues                                                                             

                                8.1.6 Recent Developments                                                                       

                                8.1.7 SWOT analysis                                                                       

                                8.1.8 Analyst View                                                                          

                8.2 Amgen                                                                         

                8.3 Genmab                                                                      

                8.4 Glaxosmithkline                                                                       

                8.5 Bristol Meyer Squibb                                                                              

                8.6 Eli Lilly                                                                           

                8.7 Immunogen                                                                               

                8.8 Novartis                                                                       

                8.9 Seattle Genetics                                                                       

                8.10 Spectrum Pharmaceuticals                                                                

  1. Competitive Landscape

                9.1 Market share analysis                                                                                            

                9.2 Merger and Acquisition Analysis                                                                                       

                9.3 Agreements, collaborations and Joint Ventures                                                                                         

                9.4 New Product Launches                                                                                         

  1. Expert Opinions

                10.1 Market Outlook                                                                                     

                10.2 Investment Opportunities                                                                                 

     Appendix                                                                                                           

  1. List of Tables
  2. List of Figures
  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
TitlePriceAdd To Cart
  1. North America Cancer Monoclonal Antibodies Market By Region, From 2015-2020 ( USD Million )
  2. North America Cancer Monoclonal Antibodies Market By Application, From 2015-2020 ( USD Million )
  3. North America Liver Market By Region, From 2015-2020 ( USD Million )
  4. North America Breast Market By Region, From 2015-2020 ( USD Million )
  5. North America Brain Market By Region, From 2015-2020 ( USD Million )
  6. North America Blood Market By Region, From 2015-2020 ( USD Million )
  7. North America Hodgkins and Non-Hodgkins lymphoma Market By Region, From 2015-2020 ( USD Million )
  8. North America Colorectal Market By Region, From 2015-2020 ( USD Million )
  9. North America Leukaemia Market By Region, From 2015-2020 ( USD Million )
  10. North America Others Market By Region, From 2015-2020 ( USD Million )
  11. North America Cancer Monoclonal Antibodies Market By Type, From 2015-2020 ( USD Million )
  12. North America Murine Antibodies Market By Region, From 2015-2020 ( USD Million )
  13. North America Chimeric and Humanised Antibodies Market By Region, From 2015-2020 ( USD Million )
  14. North America Fully Humanized Antibodies Market By Region, From 2015-2020 ( USD Million )
  15. North America Cancer Monoclonal Antibodies Market By Conjugate Cancer Therapies, From 2015-2020 ( USD Million )
  16. North America Immunoliposome Market By Region, From 2015-2020 ( USD Million )
  17. North America Radioimmunotherapy Market By Region, From 2015-2020 ( USD Million )
  18. North America ADEPT Market By Region, From 2015-2020 ( USD Million )
  19. North America Immunocytokines Market By Region, From 2015-2020 ( USD Million )
  20. North America Others Market By Region, From 2015-2020 ( USD Million )
  21. United States Cancer Monoclonal Antibodies Market By Application, From 2015-2020 ( USD Million )
  22. Canada Cancer Monoclonal Antibodies Market By Application, From 2015-2020 ( USD Million )
  23. United States Cancer Monoclonal Antibodies Market By Application, From 2015-2020 ( USD Million )
  24. United States Cancer Monoclonal Antibodies Market By Type, From 2015-2020 ( USD Million )
  25. United States Cancer Monoclonal Antibodies Market By Conjugate Cancer Therapies, From 2015-2020 ( USD Million )
  26. Canada Cancer Monoclonal Antibodies Market By Application, From 2015-2020 ( USD Million )
  27. Canada Cancer Monoclonal Antibodies Market By Type, From 2015-2020 ( USD Million )
  28. Canada Cancer Monoclonal Antibodies Market By Conjugate Cancer Therapies, From 2015-2020 ( USD Million )
Middle East And Africa Metaxalone Market By Indication (Bone Pain, Muscle Pain, Tunnel Syndromes, Joint Pain And Others), By End User (Hospitals, Clinics And Others) And By Region - Industry Analysis, Size, Share, G...
Latin America Metaxalone Market By Indication (Bone Pain, Muscle Pain, Tunnel Syndromes, Joint Pain And Others), By End User (Hospitals, Clinics And Others) And By Region - Industry Analysis, Size, Share, Growth, Tr...
Asia Pacific Metaxalone Market By Indication (Bone Pain, Muscle Pain, Tunnel Syndromes, Joint Pain And Others), By End User (Hospitals, Clinics And Others) And By Region - Industry Analysis, Size, Share, Growth, Tre...
Europe Metaxalone Market By Indication (Bone Pain, Muscle Pain, Tunnel Syndromes, Joint Pain And Others), By End User (Hospitals, Clinics And Others) And By Region - Industry Analysis, Size, Share, Growth, Trends, A...
North America Metaxalone Market By Indication (Bone Pain, Muscle Pain, Tunnel Syndromes, Joint Pain And Others), By End User (Hospitals, Clinics And Others) And By Region - Industry Analysis, Size, Share, Growth, Tr...
Metaxalone Market By Indication (Bone Pain, Muscle Pain, Tunnel Syndromes, Joint Pain And Others), By End User (Hospitals, Clinics And Others) And By Region - Industry Analysis, Size, Share, Growth, Trends, And Fore...
Middle East And Africa Narcolepsy Drugs Market By Type (Central Nervous System Stimulants, Tricyclic Antidepressants, Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, And Others), By Indication (Daytime Extre...
Latin America Narcolepsy Drugs Market By Type (Central Nervous System Stimulants, Tricyclic Antidepressants, Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, And Others), By Indication (Daytime Extreme Sleepi...
Asia Pacific Narcolepsy Drugs Market By Type (Central Nervous System Stimulants, Tricyclic Antidepressants, Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, And Others), By Indication (Daytime Extreme Sleepin...
Europe Narcolepsy Drugs Market By Type (Central Nervous System Stimulants, Tricyclic Antidepressants, Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, And Others), By Indication (Daytime Extreme Sleepiness, C...
North America Narcolepsy Drugs Market By Type (Central Nervous System Stimulants, Tricyclic Antidepressants, Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, And Others), By Indication (Daytime Extreme Sleepi...
Narcolepsy Drugs Market By Type (Central Nervous System Stimulants, Tricyclic Antidepressants, Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, And Others), By Indication (Daytime Extreme Sleepiness, Cataplex...

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2018 Market Data Forecast
All Rights Reserved.